Biotech company Biogen (NASDAQ:BIIB) beat Wall Street’s revenue expectations in Q2 CY2025, with sales up 7.3% year on year to ...

Shares of ImmunityBio (NASDAQ:IBRX) traded higher on Wednesday after the immunotherapy developer disclosed early-stage trial results for its natural killer cell therapy candidate in patients with a ...

Biotech company Biogen (NASDAQ:BIIB) will be reporting results this Thursday morning. Here’s what you need to know. Biogen beat analysts’ revenue expectations by 8.6% last quarter, reporting revenues ...

NasdaqGS:BIIB 1 Year Share Price vs Fair Value Explore Biogen's Fair Values from the Community and select yours ...

Biogen (NASDAQ:BIIB) stock rises as Q2 2025 results surpass expectations, driven by Alzheimer's drug Leqembi developed with ...

Biogen beat Q2 estimates with cost control and new launches, but MS declines and pipeline risks cloud growth. Find out why ...

Biogen Inc. Quarterly stock financials by MarketWatch. View the latest BIIB financial statements, income statements and financial ratios.

Investors in Biogen Inc (Symbol: BIIB) saw new options begin trading today, for the January 2025 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the BIIB ...